BLUDE Immucor (MM)

Transfusion Specialists From California to New England Help Guide Company NORCROSS, Ga., Nov. 14 /PRNewswire-FirstCall/ -- Immucor, Inc. (NASDAQ:BLUDE), a global leader in providing automated instrument-reagent systems to the blood transfusion industry, has created a Scientific Advisory Board to provide the company with medical and scientific input, guidance and advice. The Scientific Advisory board comprises four renowned medical scientists specializing in transfusion from around the country. The board, which will meet quarterly with Immucor executives, is charged with five primary tasks: offering medical and scientific direction for Immucor's R&D efforts; evaluating Immucor's scientific performance in the transfusion medicine field; gauging the firm's strategic plan and position in regard to medical and scientific developments; identifying scientific opportunities in transfusion medicine; and advising on scientific areas outside of transfusion medicine that would be valuable for future R&D. "We believe that the formation of this scientific board is a critical part of our future growth," commented Immucor President Dr. Nino De Chirico, adding, "Reaching out to the medical and scientific communities is part of our continuing mission to be the innovative leader in the transfusion medicine industry." About The Board Members Christopher D. Hillyer, M.D. (Board Chairman). A tenured Professor in the Department of Pathology and Laboratory Medicine, Emory University School of Medicine in Atlanta, Georgia, Dr. Hillyer serves as Director of the Transfusion Medicine Program for Emory. In this capacity, he directs the Transfusion Service at Emory University Hospital, overseeing blood banks at all affiliate institutions. He is the editor of three textbooks in transfusion medicine, and author of more than 100 articles pertaining to transfusion, HIV, cytokines and herpes viruses, most notably CMV, as well as more than 15 book chapters. He is also the President-Elect of the Board of Directors of AABB, formerly known as the American Association of Blood Banks. He received his BS from Trinity College, and his MD from the University Of Rochester School Of Medicine, with postgraduate training and fellowships in hematology-oncology, transfusion medicine and bone marrow transplantation at Tufts-New England Medical Center in Boston. Richard Benjamin, M.D. Ph.D. As the Chief Medical Officer for the Northeast Division of the American Red Cross, Dr. Benjamin oversees the medical functions of the Red Cross for New England. Previously he served as Medical Director of the Adult Transfusion Service in the Joint Program in Transfusion Medicine at Harvard University. He received Transfusion Medicine and Pathology training at the Brigham and Women's Hospital, Boston, before joining the faculty in 1995. Dr. Benjamin retains an academic position as Assistant Professor of Pathology at Harvard University where he continues to conduct clinical research in Transfusion Medicine. This work builds on his research experience as a Ph.D. student of immunology at Cambridge University, England, and post-doctoral research at Stanford University in California. Dr. Benjamin's research focuses on complications of transfusion and the optimization of a safe and adequate blood supply. Jerome L. Gottschall, M.D. Dr. Gottschall is a Professor of Pathology at the Medical College of Wisconsin and Vice President of Medical Services and Chief Medical Officer at BloodCenter of Wisconsin. His primary research focus has been in immunohematology and the disease thrombotic thrombocytopenic purpura. Over the years, Dr. Gottschall has had numerous publications in medical literature and has participated in a number of AABB, CAP and ASCP committees. He is currently the principal investigator for BloodCenter of Wisconsin in the NIH-sponsored REDS-II Study. Following undergraduate training at the University of Dayton, Dr. Gottschall received his medical degree from Ohio State University. Postgraduate training took him to the University of Kentucky for an internship in internal medicine and then a four-year residency in pathology, followed by a fellowship in blood banking/transfusion medicine at BloodCenter of Wisconsin/Medical College of Wisconsin. Ira A. Shulman, M.D. At the Keck School of Medicine at the University of Southern California in Los Angeles, Dr. Shulman serves as Professor, Vice Chair of Pathology and Director of Transfusion Medicine. He is also Director of Laboratories and Pathology at the Los Angeles County/University of Southern California (LAC+USC) Medical Center, and Medical Director of the transfusion service at the USC Kenneth Norris Cancer Hospital. He is currently chair of the AABB Clinical Transfusion Medicine Committee and the Editor and Moderator of an internationally subscribed transfusion medicine discussion group known as the e-Network Forum. Dr. Shulman earned his BA degree from UCLA, where he graduated Summa Cum Laude, and received his medical degree from the University of Southern California School of Medicine. He did his residency in pathology and fellowship in blood banking/transfusion medicine at the LAC+USC Medical Center in Los Angeles. About Immucor, Inc. Founded in 1982, Immucor manufactures and sells a complete line of reagents and systems used by hospitals, reference laboratories and donor centers to detect and identify certain properties of the cell and serum components of blood prior to transfusion. Immucor markets a complete family of automated instrumentation for all of our market segments. For more information on Immucor, please visit our website at http://www.immucor.com/. This press release contains forward-looking statements as that term is defined in the Private Securities Reform Act of 1995, including, without limitation, statements concerning the Company's expectations, beliefs, intentions or strategies regarding the future. All forward-looking statements included in this document are based on information available to the Company on the date hereof, and the Company assumes no obligation to update any such forward-looking statements. Further risks are detailed in the Company's filings with the Securities and Exchange Commission, including those set forth in the Company's most recent Form 10-K and Quarterly Reports on Form 10. DATASOURCE: Immucor, Inc. CONTACT: Edward Gallup of Immucor, Inc., +1-770-441-2051 Web site: http://www.immucor.com/

Copyright